2:01 PM
 | 
Jul 12, 2018
 |  BC Extra  |  Company News

Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications.

Immatics will receive $54 million up front and is eligible for $550 million in milestones for each product the partners develop, plus royalties up to double digits. Genmab...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >